» Articles » PMID: 11447837

The Role of Post-translational Modification in Beta-amyloid Precursor Protein Processing

Overview
Specialty Biochemistry
Date 2001 Jul 13
PMID 11447837
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The beta-amyloid precursor protein (APP) plays a pivotal role in the early stages of neurodegeneration associated with Alzheimer's disease. An alteration in the processing pattern of the protein results in an increase in the generation of the 40-42-amino-acid beta-amyloid (A beta) peptide, which coalesces to form insoluble, extracellular amyloid deposits. A greater understanding of the factors that influence APP processing may assist in the design of effective therapeutic agents to halt progression of Alzheimer's disease. APP is a sialoglycoprotein with two potential N-linked glycosylation sites, one of which may contain a complex oligosaccharide chain. An alteration in the glycosylation state of APP by the generation of oligomannosyl oligosaccharides results in a decrease in the secretion of the neuroprotective, soluble form of the protein and a parallel increase in the deposition of the cellular protein within the perinuclear region of the cell. Conversely, the attachment of additional terminal sialic acid residues on to the oligosaccharide chain results in an increase in secretion of soluble APP (sAPP alpha). One factor that has been widely reported to alter APP processing is the activation of protein kinase C (PKC). This process has been characterized using synaptosomal preparations, which suggests that the PKC action is occurring at the level of the plasma membrane. Furthermore, when cells are transfected with the sialyltransferase enzyme, there is a direct relationship between the sialylation potential of APP and the fold stimulation of sAPP alpha, after PKC activation. These results suggest that the post-translational modification of APP by glycosylation is a key event in determining the processing of the protein.

Citing Articles

Serine phosphorylation mimics of Aβ form distinct, non-cross-seeding fibril morphs.

Sanagavarapu K, Meisl G, Lattanzi V, Bernfur K, Frohm B, Olsson U Chem Sci. 2024; .

PMID: 39494375 PMC: 11529392. DOI: 10.1039/d3sc06343g.


Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease.

Salasova A, Monti G, Andersen O, Nykjaer A Mol Neurodegener. 2022; 17(1):74.

PMID: 36397124 PMC: 9673319. DOI: 10.1186/s13024-022-00576-2.


The Amyloid-β Pathway in Alzheimer's Disease.

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim S Mol Psychiatry. 2021; 26(10):5481-5503.

PMID: 34456336 PMC: 8758495. DOI: 10.1038/s41380-021-01249-0.


N-Terminal Modified Aβ Variants Enable Modulations to the Structures and Cytotoxicity Levels of Wild-Type Aβ Fibrils through Cross-Seeding.

Hu Z, Au D, Cruceta L, Vugmeyster L, Qiang W ACS Chem Neurosci. 2020; 11(14):2058-2065.

PMID: 32603584 PMC: 7647724. DOI: 10.1021/acschemneuro.0c00316.


Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.

Ahmed T, Zahid S, Mahboob A, Farhat S Curr Neuropharmacol. 2016; 15(4):480-494.

PMID: 27012953 PMC: 5543671. DOI: 10.2174/1570159X14666160325121145.